Trials / Terminated

TerminatedNCT00089713

Systolic Pressure Efficacy and Safety Trial of Alagebrium (SPECTRA)

Effect of ALT-711 in Combination With Fixed-Dose Hydrochlorothiazide Therapy on Systolic Blood Pressure in Hypertensive Patients

Status: Terminated
Phase: Phase 2
Study type: Interventional
Enrollment: 392 (planned)

Sponsor: Synvista Therapeutics, Inc · Industry
Sex: All
Age: 45 Years
Healthy volunteers: Not accepted

Summary

This study comprises a 3- to 6-week hydrochlorothiazide run in phase, followed by a 12 week double-blind treatment phase, followed by a 2 week single-blind follow-up hydrochlorothiazide treatment phase. The combined total duration of patient participation is approximately 17-20 weeks. Four double-blind treatment groups approximately equal in size (98) will comprise the study population: placebo or various alagebrium dose groups (10, 50, or 150 mg/day).

Conditions

Hypertension

Interventions

Type	Name	Description
DRUG	alagebrium chloride (ALT-711)

Timeline

Start date: 2004-03-01
First posted: 2004-08-12
Last updated: 2010-02-08

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00089713. Inclusion in this directory is not an endorsement.